A Prospective Survey on Safety of Sustained-Release Theophylline in Treatment of Asthma and COPD

DOI Web Site Web Site PubMed 43 References
  • Makino Sohei
    Committee on the Safety of Sustained-Release Theophylline and Injectable Methylxanthines (CST), Committee for Asthma Prevention and Management Guidelines in the Japanese Society of Allergology
  • Adachi Mitsuru
    Committee on the Safety of Sustained-Release Theophylline and Injectable Methylxanthines (CST), Committee for Asthma Prevention and Management Guidelines in the Japanese Society of Allergology
  • Ohta Ken
    Committee on the Safety of Sustained-Release Theophylline and Injectable Methylxanthines (CST), Committee for Asthma Prevention and Management Guidelines in the Japanese Society of Allergology
  • Kihara Norio
    Committee on the Safety of Sustained-Release Theophylline and Injectable Methylxanthines (CST), Committee for Asthma Prevention and Management Guidelines in the Japanese Society of Allergology
  • Nakajima Sigenori
    Committee on the Safety of Sustained-Release Theophylline and Injectable Methylxanthines (CST), Committee for Asthma Prevention and Management Guidelines in the Japanese Society of Allergology
  • Nishima Sankei
    Committee on the Safety of Sustained-Release Theophylline and Injectable Methylxanthines (CST), Committee for Asthma Prevention and Management Guidelines in the Japanese Society of Allergology
  • Fukuda Takeshi
    Committee on the Safety of Sustained-Release Theophylline and Injectable Methylxanthines (CST), Committee for Asthma Prevention and Management Guidelines in the Japanese Society of Allergology
  • Miyamoto Terumasa
    Committee on the Safety of Sustained-Release Theophylline and Injectable Methylxanthines (CST), Committee for Asthma Prevention and Management Guidelines in the Japanese Society of Allergology

Search this article

Abstract

Background: Theophylline is a useful drug for the treatment of asthma. The Asthma Prevention and Management Guidelines (JGL) recommend use of sustained-release theophylline products as controllers and of injectable aminophylline products as relievers. The Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention, the NHLB/WHP Workshop Report 1995 (GINA, 1995) and guidelines in Western countries recommend sustained-release theophylline, but not as positively as in the JGL. The aim of this survey was to determine the occurrence of serious adverse reactions.<br> Methods: The survey was conducted in 66 institutions staffed by physicians certified by the Japanese Society of Allergology (JSA). The target diseases were asthma and COPD including chronic bronchitis and pulmonary emphysema, which are indications for use of sustained-release theophylline products in Japan.<br> Results: 3,921 patients were included in the safety evaluation. No serious adverse reactions were observed among the patients in this survey, although 54 patients (1.38%) exhibited non-serious adverse reactions. The incidence of adverse reactions was found to be high in patients who had begun use of sustained-release theophylline products at the time of registration in this survey, and in patients who were concomitantly taking macrolide antibiotics.<br> Conclusions: The present survey demonstrates that sustained-release theophylline is safe, as long as used appropriately, although adverse reactions tend to develop early after initiation of administration.<br>

Journal

References(43)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top